THE BINDING OF THE ADENOSINE-A2 RECEPTOR-SELECTIVE AGONIST [H-3] CGS-21680 TO RAT CORTEX DIFFERS FROM ITS BINDING TO RAT STRIATUM

被引:92
|
作者
JOHANSSON, B
GEORGIEV, V
PARKINSON, FE
FREDHOLM, BB
机构
[1] Department of Pharmacology, Karolinska Institutet, Stockholm
基金
英国医学研究理事会;
关键词
ADENOSINE RECEPTORS; AUTORADIOGRAPHY; (CAT); (RAT);
D O I
10.1016/0922-4106(93)90066-I
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The binding of the reportedly A2A selective agonist CGS 21680 (2-[p-(2-carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamidoadenosine) to cortex and striatum was examined in parallel using quantitative receptor autoradiography. [H-3]CGS 21680 bound to a single site in rat striatum with K(D) 2.3 nM and B(max) 320 fmol/mg grey matter. In addition [H-3]CGS 21680 bound to a single site in the cerebral cortex with K(D) 47 nM and B(max) 100 fmol/mg grey matter. In cat cortex [H-3]CGS 21680 (2 nM) binding was strong and particularly evident in the most superficial layers. The potency order for inhibition of 2 nM [H-3]CGS 21680 binding to rat striatum was NECA (5'-N-ethylcarboxamidoadenosine; IC50 9.0 nM) > 2-CADO (2-chloroadenosine; 87 nM) > R-PIA (N6-(R)-phenylisopropyladenosine; 110 nM). The potency order for inhibition of 2 nM [H-3]CGS 21680 binding to rat cortex was NECA (3.0 nM) > 2-CADO (14 nM) greater-than-or-equal-to R-PIA (16 nM). Gpp(NH)p (5'-guanylyl imidodiphosphate) inhibited [H-3]CGS 21680 binding to both cortex and striatum, but more potently in cortex (IC50 100 nM vs. 470 nM). The present results show that there is a cortical binding site for [H-3]CGS 21680 which appears to be different from the the striatal A2A receptor, the A2B receptor and the A1 receptor.
引用
收藏
页码:103 / 110
页数:8
相关论文
共 50 条
  • [1] FURTHER CHARACTERIZATION OF [H-3] CGS-21680 BINDING-SITES IN THE RAT STRIATUM AND CORTEX
    KIRK, IP
    RICHARDSON, PJ
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 (02) : 537 - 543
  • [2] EFFECTS OF MONOVALENT AND DIVALENT IONS ON THE BINDING OF THE ADENOSINE ANALOG CGS-21680 TO ADENOSINE-A2 RECEPTORS IN RAT STRIATUM
    JOHANSSON, B
    PARKINSON, FE
    FREDHOLM, BB
    [J]. BIOCHEMICAL PHARMACOLOGY, 1992, 44 (12) : 2365 - 2370
  • [3] FURTHER CHARACTERIZATION OF THE BINDING OF THE ADENOSINE RECEPTOR AGONIST [H-3] CGS-21680 TO RAT-BRAIN USING AUTORADIOGRAPHY
    JOHANSSON, B
    FREDHOLM, BB
    [J]. NEUROPHARMACOLOGY, 1995, 34 (04) : 393 - 403
  • [4] EFFECTS OF CGS-21680, A SELECTIVE ADENOSINE-A2 RECEPTOR AGONIST, ON ERYTHROPOIETIN (EPO) PRODUCTION
    OHIGASHI, T
    BROOKINS, J
    FISHER, JW
    [J]. CLINICAL RESEARCH, 1992, 40 (04): : A819 - A819
  • [5] [H-3] CGS-21680, A SELECTIVE A2 ADENOSINE RECEPTOR AGONIST DIRECTLY LABELS A2-RECEPTORS IN RAT-BRAIN
    JARVIS, MF
    SCHULZ, R
    HUTCHISON, AJ
    DO, UH
    SILLS, MA
    WILLIAMS, M
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1989, 251 (03): : 888 - 893
  • [6] CGS-21680 - A POTENT SELECTIVE ADENOSINE A2 RECEPTOR AGONIST
    WEBB, RL
    SILLS, MA
    CHOVAN, JP
    BALWIERCZAK, JL
    FRANCIS, JE
    [J]. CARDIOVASCULAR DRUG REVIEWS, 1992, 10 (01): : 26 - 53
  • [7] INHIBITION OF [H-3] CGS21680 BINDING TO THE ADENOSINE-A2 RECEPTOR BY 2-SUBSTITUTED ADENOSINE-ANALOGS
    WILEY, DM
    SZABO, I
    MAGUIRE, MH
    [J]. FASEB JOURNAL, 1991, 5 (06): : A1768 - A1768
  • [8] DIRECT AUTORADIOGRAPHIC LOCALIZATION OF ADENOSINE-A2 RECEPTORS IN THE RAT-BRAIN USING THE A-2-SELECTIVE AGONIST, [H-3] CGS 21680
    JARVIS, MF
    WILLIAMS, M
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 168 (02) : 243 - 246
  • [9] EFFECTS OF THE SELECTIVE ADENOSINE-A2 RECEPTOR AGONIST CGS 21680 ON INVITRO ELECTROPHYSIOLOGY, CAMP FORMATION AND DOPAMINE RELEASE IN RAT HIPPOCAMPUS AND STRIATUM
    LUPICA, CR
    CASS, WA
    ZAHNISER, NR
    DUNWIDDIE, TV
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1990, 252 (03): : 1134 - 1141
  • [10] BINDING CHARACTERISTICS OF THE ADENOSINE-A(2) RECEPTOR-LIGAND [H-3] CGS-21680 TO HUMAN PLATELET MEMBRANES
    VARANI, K
    BOREA, PA
    GUERRA, L
    DIONISOTTI, S
    ZOCCHI, C
    ONGINI, E
    [J]. BIOCHEMICAL PHARMACOLOGY, 1994, 48 (08) : 1658 - 1661